Tutoriels cliniques
Un parcours complet pour les médecins et les patients avertis : comment un bilan génomique est produit et interprété, comment détecter les processus pathologiques des années à l'avance, et ce que les données probantes soutiennent réellement.
Chaque tutoriel de ce parcours est relu de façon indépendante par un second modèle pour en vérifier l'exactitude clinique avant publication.
Reading a Genome
What a 30× Whole Genome Sequence Actually Is — and What It Still Cannot Tell You
A clinical reading guide to 30× whole genome sequencing: what the depth figure means, how it differs from a SNP array and an exome, and the specific variant classes a normal genome report does not exclude.
From Blood Draw to Variant List: What the Genomic Pipeline Does, and Where It Fails Quietly
A clinician's guide to the five stages between a sample and a genomic report — what each accomplishes, why millions of variants is a normal result, and how a poorly read region becomes a falsely reassuring negative.
Pathogenic, Benign, or Uncertain: How a Variant Gets Its Verdict — and What Each Verdict Licenses
A clinician's guide to reading the classification column on a genomic report: what dbSNP, gnomAD and ClinVar each contribute, why a variant of uncertain significance must never drive management, and how to explain penetrance to a patient who has just been called 'pathogenic'.
The 94th Percentile Is Not a 94% Risk: Reading Polygenic Scores in Cardiovascular Prevention
A practical guide to interpreting a polygenic risk score report — how the number is built, how to convert a percentile into absolute risk, why the score may not apply to your patient at all, and why a high score usually changes timing and intensity rather than diagnosis.
Reading a Pharmacogenomic Report: The Gene–Drug Pairs That Actually Change a Prescription
A clinician's guide to interpreting metabolizer phenotype labels, the gene–drug pairs with evidence strong enough to act on today, and why a genotype describes capacity rather than current enzyme activity.
HLA Typing in Practice: The Results That Prevent a Severe Drug Reaction — and the Ones That Only Rule Out Disease
A clinical guide to reading HLA results: which alleles change prescribing today, why a coeliac-permissive type is not a diagnosis, and when a genome-derived HLA call must be confirmed before you act on it.
SNPs and SNP Panels: Reading a Curated Variant Report Without Over-Reading It
A clinical guide to what common single-nucleotide variants and curated panels genuinely deliver — pharmacogenomic phenotypes, HLA risk types, polygenic percentiles — and the structural reasons a negative panel in a symptomatic patient tells you almost nothing.
Multi-Omic Integration
Genotype Sets the Hand, Bloodwork Shows How It Is Being Played: Pairing Genetic Risk With Movable Cardiometabolic Markers
A clinical guide to interpreting genetic risk alongside blood biomarkers in cardiovascular prevention — why apoB beats LDL-C, where Lp(a) fits, how to catch insulin resistance a decade early, and why a laboratory reference range is not a target.
Imaging the Longevity Workup: What Calcium Scoring, CCTA, Whole-Body MRI, DEXA and CPET Each Buy — and What Each Costs
A practical framework for sequencing advanced imaging in preventive practice: why a picture of disease outranks a score that predicts it, where coronary calcium goes blind in younger patients, and how to weigh whole-body MRI's occult cancers against its cascades.
When the Layers Agree: Reading Stool and Broad Protein Panels Alongside the Genome
A clinical guide to interpreting microbiome and high-plex proteomic reports — what each layer actually measures, how much weight it deserves, and why convergence across independent layers is the only signal strong enough to act on.
The Precision Longevity Workup, in the Order It Should Actually Be Run
A sequenced account of the advanced longevity workup — genome, blood, imaging, function, microbiome, proteomics, liquid biopsy — with a stated confidence on every element and a method for turning fifty abnormal values into one first action.
The Five Horsemen
Insulin Resistance in the Compensated Phase: Reading the Decade Before Type 2 Diabetes
Type 2 diabetes is the late visible stage of a storage problem that begins years earlier. How to detect metabolic dysfunction while fasting glucose and HbA1c are still normal, how to stage the liver without a biopsy, and how to sequence the response.
Plaque as Cumulative Exposure: apoB, Lp(a), Imaging and Inherited Risk in the Patient Whose Cholesterol Looks Fine
A clinical framework for atherosclerosis as lifetime particle exposure rather than a ten-year risk percentage — how to combine apoB, Lp(a), coronary imaging and inherited risk into a decision about when to start treating, and how to explain a 'normal' lipid panel that isn't reassuring.
The Third Horseman: Reading Alzheimer's and Parkinson's Risk Two Decades Before Symptoms
A clinical walkthrough of the Alzheimer's cascade, APOE ε4 counseling, the plasma biomarkers that made pre-symptomatic detection real, and the risk-reduction plan the evidence actually supports — plus the Parkinson's prodrome you can ask about in a routine history.
Cancer as an Evolutionary Process: Inherited Risk, Modifiable Risk, and Which Screens Have Mortality Evidence
A clinical account of where cancer can actually be interrupted — germline syndromes that change management now, the metabolic and inflammatory contribution, and the hard line between screens with mortality data and screens with detection data only.
Autoimmunity Before It Declares: Tolerance, Triggers and the Pre-Clinical Antibody Window
How self-tolerance is enforced and how it fails, why an HLA risk genotype is not a prediction, and how to use — and not misuse — autoantibodies in the years before symptoms appear.
The Hallmarks of Aging
The Primary Hallmarks of Aging: Which Damage You Can Actually Measure
A clinical read of the five upstream hallmarks — genomic instability, telomere attrition, epigenetic drift, loss of proteostasis and disabled autophagy — separating what is measurable in a patient from what is mechanism only, and what has human endpoint data from what does not.
Nutrient Sensing, Mitochondria and Senescence: Reading the Antagonistic Hallmarks in a Real Patient
The three aging processes that begin as protective responses and become drivers — what can actually be measured in clinic today, and where the human evidence for rapamycin, metformin, NAD precursors and senolytics genuinely stands.
The Integrative Hallmarks of Aging: Reading Frailty, Inflammation and Regenerative Decline in the Consultation Room
The fourth-tier hallmarks — regenerative decline, altered tissue signaling, inflammaging and gut dysbiosis — are the ones that actually walk into clinic. How to measure them with a dynamometer, a hallway and a short lab panel, and which single prescription moves several at once.
The Omic Layers
Reading an Epigenetic Age Result: What the Number Is Worth
A clinical guide to interpreting biological-age and pace-of-aging results: what the epigenome is, what each generation of clock was trained to predict, why repeat testing of the same sample can differ by years, and how to counsel a patient who wants to buy one.
Proteome and Metabolome: Reading What Is Happening Now
A clinical guide to protein and metabolite measurement — why these layers report present state rather than inherited risk, what broad panels can and cannot support, and how to judge an organ-age or metabolomic result you did not order.
The Aging Immune System: Reading Inflammaging, Immunosenescence and the Immune Panel
How immune function changes with age, why chronic sterile inflammation reinforces that decline, which immune measurements are worth ordering in ordinary practice, and which interventions have real evidence behind them.
The Microbiome in Clinic: The Barrier, Butyrate, and What Actually Justifies an Action
A clinician's guide to reading gut microbiome results honestly — how barrier failure becomes systemic inflammation, why fiber and fermented foods outrank every supplement on trial evidence, and which drug–microbiome interactions change prescribing.
Mechanisms at Clinical Depth
Senescent Cells and Senolytics: A Clinician's Guide to Where the Evidence Actually Stops
What a senescent cell is, how a small population drives systemic inflammation, and an honest account of senolytic human data — early-phase, mechanistic, and short of any outcome a patient cares about.
Growth Versus Maintenance: Fasting, Protein and the Rapamycin Question
A clinical account of the nutrient-sensing trade-off — what actually induces cellular clean-up in humans rather than in mice, why muscle wins the argument in an older patient, and where the rapamycin and metformin evidence genuinely stops.
Mitochondrial Function in the Clinic: Measuring Capacity, Recognizing Inherited Disease, and Ranking What Actually Works
A practical account of what mitochondrial function means clinically — why there is no blood test for capacity but an excellent functional one, how to recognize inherited mitochondrial disease and refer, and an honest evidence ranking of the interventions patients ask about.
NAD+ Precursors: Reading the Trial Evidence and Answering the Patient Who Asks
Why the NAD+ pool falls with age is a consumption problem, not a production failure — and why that reframes every question about NR, NMN and intravenous NAD. What the human trials actually measured, what they did not, and how to answer the patient holding the bottle.
